Search
Technetium Tc-99m tilmanocept
go.drugbank.com/drugs/DB09266ApprovedIt is a macromolecule consisting of multiple units of diethylenetriaminepentaacetic acid (DTPA) and mannose, each covalently attached to a 10 kDa dextran backbone [FDA Label]. … It achieves high overall accuracy in detecting SLN [A32169].
Thiothixene
go.drugbank.com/drugs/DB01623ApprovedA thioxanthine used as an antipsychotic agent. Its effects are similar to the phenothiazine antipsychotics.
Products: Navane Cap 2mgMD-0727
go.drugbank.com/drugs/DB05948InvestigationalMD-0727 is a novel, potent cholesterol absorption inhibitor (CAI) under investigation for the treatment of hypercholesterolemia (high cholesterol.
Casirivimab
go.drugbank.com/drugs/DB15941ApprovedInvestigational[A221495] On November 21 2020, the FDA authorized emergency approval of REGEN-COV2 to treat mild to moderate COVID-19 in patients aged 12 years and older. … Casirivimab and imdevimab are investigational recombinant human IgG1 monoclonal antibodies that, at this time, are not officially approved by the FDA.
Osemozotan
go.drugbank.com/drugs/DB05339ExperimentalMN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by MediciNova for the treatment of anxiety disorders beginning with Generalized Anxiety Disorder (GAD)
Ivosidenib
go.drugbank.com/drugs/DB14568ApprovedInvestigational[L46287] It was fully approved by the EMA in May 2023.[L46596] … [L48781] In February 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of ivosidenib and recommended it be granted marketing authorization for the treatment
Benzoic acid
go.drugbank.com/drugs/DB03793ApprovedInvestigationalIt is conjugated to GLYCINE in the liver and excreted as hippuric acid.
Mixtures: SKINOREN %20 KREM, 30 G, ARTU 100 ML SURUPBG-777
go.drugbank.com/drugs/DB05839ExperimentalBG-777 is an immunomodulator with proven efficacy against viral and bacterial infections in preclinical studies.
Cinaciguat
go.drugbank.com/drugs/DB16126InvestigationalCinaciguat is under investigation in clinical trial NCT01067859 (A Phase Iib Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 ΜG/h, 10 ΜG/h) Given Intravenously to Patients
Norelgestromin
go.drugbank.com/drugs/DB06713ApprovedInvestigationalIt is administered transdermally in combination with the estrogen [ethinyl estradiol], delivering both hormones systemically over a 7-day wear period.
Mixtures: EVRA TRANSDERMAL PATCH (6 mg/600 mcg), Evra -(6/0.75)